Clinical trials: Rectum Carcinoma
Colorectal Neoplasms, Neoplasm Metastasis
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.
- Trial name
- AFFIRM (NCT00851084)
- Testing
- aflibercept, oxaliplatin, 5-FU
- Where
- 37 sites in Australia, Germany and 5 more
- Volunteers
- 268 people
- Sponsor
- Sanofi
Colorectal Cancer
Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer
The primary objective of this Phase 1 study is to identify the recommended dose of capiri and of sunitinib for combination therapy subsequent phase II trials.
- Trial name
- sutent-capiri (NCT00777478)
- Testing
- capiri-sutent
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Radboud University Medical Center
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006115
- Testing
- FOLFIRI regimen, FOLFOX regimen, fluorouracil
- Where
- 16 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Rectal Cancer
Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy
The purpose of this study is to determine the role of endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values in predicting the tumor regression after concurrent…
- Trial name
- NCT01582750
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00023933
- Testing
- iodine I 131 monoclonal antibody CC49-deltaCH2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer, Colorectal Cancer
Endoscopic Visualisation of Anastomosis in Colorectal Cancer Surgery
A randomised feasibility study into the use of endoscopic visualisation of rectal anastomosis vs. current practice and the effect on anastomotic leak rates in patients undergoing rectal surgery for bowel cancer in a tertiary…
- Conditions
- Rectal Cancer, Colorectal Cancer, Anastomotic Leak, Intraoperative Endoscopy
- Trial name
- EVACCS (NCT04738240)
- Testing
- Intra-operative endoscopy
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Plymouth
Colorectal Cancer
Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with metastatic…
- Trial name
- NCT00003220
- Testing
- bryostatin 1
- Where
- 2 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Cancer of Rectum, Cancer of the Rectum
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
The purpose of this research study is to look at how tumors responds to a short course of radiation (5 days) followed by 8 cycles of chemotherapy.
- Conditions
- Cancer of Rectum, Cancer of the Rectum, Neoplasm, Rectum, Rectal Cancer
- Trial name
- NORMAL-R (NCT02641691)
- Testing
- Radiation, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Rectal Cancer, Anastomotic Leak
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
LifeSeal™ Kit, surgical sealant designed for staple-line reinforcement that is applied over the anastomotic line to prevent bowel content leakage until full physiological function is restored.
- Trial name
- NCT02907385
- Testing
- LifeSeal™ Kit
- Where
- 39 sites in United States, Belgium and 5 more
- Volunteers
- 736 people
- Sponsor
- LifeBond Ltd.
Colon Cancer, Rectal Cancer
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
The purpose of this study is to find out how well patients with cancer of the rectum do if they get all of their other treatment - chemotherapy by itself followed by chemotherapy and radiation together - before surgery.
- Trial name
- NCT01363843
- Testing
- FOLFOX6, RT with concurrent chemotherapy, Surgery
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- William Sikov MD
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
This phase I/II trial tests the safety, side effects, best dose, and efficacy of FOLFOX and bevacizumab in combination with botensilimab and balstilimab (3B-FOLFOX) in treating patients with microsatellite stable (MSS) colorectal…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT05627635
- Testing
- Balstilimab, Bevacizumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Rectal Neoplasm
Radiotherapy & Total Neoadjuvant Therapy for Recurrent Rectal Cancer in Previously Irradiated Patients, an Italian Association for Radiotherapy and Clinical Oncology (AIRO)-GI Platform: a Multi-centre Prospective Observational Study
The introduction of neoadjuvant chemoradiation therapy (CRT) and the use of advanced surgical techniques have led to a reduction in mortality and recurrence rates for rectal cancer, the rate of which currently stands at 4-8%.
- Trial name
- RETRY (NCT05984576)
- Testing
- Reirradiation
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rectal Cancer
A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer
The purpose of this study is to determine the pathological complete tumor response rate.
- Trial name
- NCT02694718
- Testing
- Capecitabine, Oxaliplatin
- Where
- 6 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Rectal Cancer
Pilot Randomized Evaluation of Butyrate Irrigation Before Ileostomy Closure on the Colonic Mucosa in Rectal Cancer Patients (BUTYCLO)
Low Anterior resection with total mesorectal excision and diversion loop ileostomy is a gold standard surgical treatment in rectal cancer.
- Trial name
- BUTYCLO (NCT04795180)
- Testing
- Irrigations trough the efferent limb of loop ileostomy
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Recurrent Colon Cancer, Recurrent Rectal Cancer
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
This randomized phase III trial is studying giving irinotecan and cetuximab together with bevacizumab to see how well it works compared with giving irinotecan and cetuximab alone in treating patients with metastatic colorectal…
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- NCT00499369
- Testing
- irinotecan hydrochloride, leucovorin calcium, fluorouracil
- Where
- 382 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Adenocarcinoma, Colon Cancer
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Data from a prior phase II study of single agent cabozantinib in metastatic, refractory colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal mouse models utilizing cabozantinib combined with…
- Conditions
- Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer
- Trial name
- NCT04963283
- Testing
- Cabozantinib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Colorado, Denver
Neoadjuvant Treatment, Rectal Cancer
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer
- Conditions
- Neoadjuvant Treatment, Rectal Cancer, Bevacizumab, Radiotherapy
- Trial name
- NCT05111860
- Testing
- Bevacizumab+mFOLFOX6
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Phase 2, Sacituzumab Tirumotecan
Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum
To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.
- Conditions
- Phase 2, Sacituzumab Tirumotecan, Refractory Metastatic, Unresectable Squamous
- Trial name
- NCT07511023
- Testing
- Sacituzumab Tirumotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer
Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
This cohort study is divided into two parts: Part A: Registry Cohort All patients with non-metastatic, MMRd/MSI-H colorectal cancers (and other gastrointestinal cancers for exploratory analysis) who have signed the general…
- Conditions
- Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer, Microsatellite Instability-High Colorectal Cancer, Stage II Colorectal Cancer
- Trial name
- RESIST (NCT07829081)
- Testing
- Active surveillance after complete response to immunotherapy in MMRd GI cancers, Stand of Care
- Where
- 3 sites in Switzerland
- Volunteers
- 234 people
- Sponsor
- University Hospital, Basel, Switzerland
Rectal Cancer
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
This study involves the use of Oxaliplatin, 5-Fluorouracil (5-FU), Leucovorin and Cetuximab, which are all medicines approved by the Food and Drug Administration (FDA) and are commercially available.
- Trial name
- NCT00580073
- Testing
- FOLFOX4, Cetuximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.